Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Project Grant - PA: Pandemic Preparedness and Health Emergencies Research

University of Toronto

$100,000.00

Selective Targeting of Respiration in Human Fungal Pathogens to Address the Rapidly Escalating Threat of Drug-resistant Infection

EF 2025-26

Résumé
Fungal pathogens infect billions of people and cause ~2.5 million deaths worldwide annually. A major factor underlying the mortality of fungal infections in the bloodstream has been the limited number of available treatments. While >20 classes of mechanistically distinct antibiotics exist for bacterial infections, only three major classes of antifungals are currently available. Alarmingly, infections resistant to each class are rapidly increasing and no new class has been approved for clinical use in decades. In response to this distressing situation, we propose an innovative approach to developing an inhibitor of Cytochrome b (Cob) as a new treatment strategy for infection by fungal pathogens. This target operates in a large complex within the mitochondria of cells, which enables them to use oxygen to generate energy in a process called respiration. We have already identified a potent inhibitor of Cob that selectively impairs growth in the lab of pathogenic fungi, but not human cells. Impairing its further development, however, the compound is not stable enough, when circulating in the body, to be used to treat infections in animals. Fortunately, we recently discovered that one of the most widely used antifungal drugs in the clinic (fluconazole) stabilizes our Cob inhibitor in mice by blocking its metabolism within the liver. Equally exciting, when administered together, the Cob inhibitor makes fluconazole a more effective antifungal by enabling it to kill fungi, not just prevent their growth. Our goal now is to translate these findings into the development of a new, clinically-relevant combination antifungal that could be rapidly transitioned to trial in patients as well as understand the mechanisms by which the combination has improved antifungal activity and reduces the emergence of drug-resistant fungal infections.
Programme
Project Grant - PA: Pandemic Preparedness and Health Emergencies Research
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
569212
Name
Cowen Leah E
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Microbiology & Infectious Diseases
Projecttitle
Selective Targeting of Respiration in Human Fungal Pathogens to Address the Rapidly Escalating Threat of Drug-resistant Infection
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - PA: Pandemic Preparedness and Health Emergencies Research
Keyworddelim
Antifungal Drug Development; Antifungal Drug Resistance; Candida Albicans; Candida Auris; Drug Combinations; Functional Genomics; Fungal Pathogen; Mitochondria; Pharmacology; Structure-Guided Drug Design
Abstract
Fungal pathogens infect billions of people and cause ~2.5 million deaths worldwide annually. A major factor underlying the mortality of fungal infections in the bloodstream has been the limited number of available treatments. While >20 classes of mechanistically distinct antibiotics exist for bacterial infections, only three major classes of antifungals are currently available. Alarmingly, infections resistant to each class are rapidly increasing and no new class has been approved for clinical use in decades. In response to this distressing situation, we propose an innovative approach to developing an inhibitor of Cytochrome b (Cob) as a new treatment strategy for infection by fungal pathogens. This target operates in a large complex within the mitochondria of cells, which enables them to use oxygen to generate energy in a process called respiration. We have already identified a potent inhibitor of Cob that selectively impairs growth in the lab of pathogenic fungi, but not human cells. Impairing its further development, however, the compound is not stable enough, when circulating in the body, to be used to treat infections in animals. Fortunately, we recently discovered that one of the most widely used antifungal drugs in the clinic (fluconazole) stabilizes our Cob inhibitor in mice by blocking its metabolism within the liver. Equally exciting, when administered together, the Cob inhibitor makes fluconazole a more effective antifungal by enabling it to kill fungi, not just prevent their growth. Our goal now is to translate these findings into the development of a new, clinically-relevant combination antifungal that could be rapidly transitioned to trial in patients as well as understand the mechanisms by which the combination has improved antifungal activity and reduces the emergence of drug-resistant fungal infections.
Competitiondate
202603
Approvedterm2
1 yr 0 mth
Pinamesdelim
Cowen, Leah E
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~